3 Reasons HAE is Risky and 1 Stock to Buy Instead
Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65.64 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
